BioNexus Gene Lab Corp. Goodwill, Foreign Currency Translation Gain (Loss)
BioNexus Gene Lab Corp. (BGLC) reported Goodwill, Foreign Currency Translation Gain (Loss) of $9.87 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-31.
Discontinued › Income Statement › Other Income
us-gaap:GoodwillForeignCurrencyTranslationGainLoss · last filed 2020-03-31
- BioNexus Gene Lab Corp. goodwill, foreign currency translation gain (loss) for the quarter ending 2019-12-31 was $21.13K.
- BioNexus Gene Lab Corp. goodwill, foreign currency translation gain (loss) for the quarter ending 2019-09-30 was -$10.80K, a 267.92% decline year-over-year.
- BioNexus Gene Lab Corp. goodwill, foreign currency translation gain (loss) for the quarter ending 2019-06-30 was -$2.02K.
- BioNexus Gene Lab Corp. goodwill, foreign currency translation gain (loss) for the quarter ending 2019-03-31 was $17.14K, a 878.04% increase year-over-year.
- BioNexus Gene Lab Corp. goodwill, foreign currency translation gain (loss) for fiscal 2019 was $9.87K.
- BioNexus Gene Lab Corp. goodwill, foreign currency translation gain (loss) for fiscal 2018 was -$41.03K.
| Period end | Goodwill, Foreign Currency Translation Gain (Loss) 3 month | Goodwill, Foreign Currency Translation Gain (Loss) 6 month | Goodwill, Foreign Currency Translation Gain (Loss) 9 month | Goodwill, Foreign Currency Translation Gain (Loss) 12 month |
|---|---|---|---|---|
| 2019-12-31 | $21.13K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-31 | $10.33K derived: sum of 2 quarters · filed 2020-03-31 | $8.31K derived: sum of 3 quarters · filed 2020-03-31 | $9.87K 10-K · filed 2020-03-31 |
| 2019-09-30 | -$10.80K 10-Q · filed 2019-11-14 | -$12.82K derived: sum of 2 quarters · filed 2019-11-14 | -$11.26K 10-Q · filed 2019-11-14 | -$30.46K derived: sum of 4 quarters · filed 2020-03-31 |
| 2019-06-30 | -$2.02K 10-Q · filed 2019-08-09 | -$455.00 10-Q · filed 2019-08-09 | -$19.65K derived: sum of 3 quarters · filed 2020-03-31 | -$13.22K derived: sum of 4 quarters · filed 2020-03-31 |
| 2019-03-31 | $17.14K 10-Q · filed 2019-05-15 | -$17.64K derived: sum of 2 quarters · filed 2020-03-31 | -$11.20K derived: sum of 3 quarters · filed 2020-03-31 | -$25.65K derived: sum of 4 quarters · filed 2020-03-31 |
| 2018-12-31 | -$34.78K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-31 | -$28.35K derived: sum of 2 quarters · filed 2020-03-31 | -$42.79K derived: sum of 3 quarters · filed 2020-03-31 | -$41.03K 10-K · filed 2020-03-31 |
| 2018-09-30 | $6.43K 10-Q · filed 2019-11-14 | -$8.01K derived: sum of 2 quarters · filed 2019-11-14 | -$6.25K 10-Q · filed 2019-11-14 | |
| 2018-06-30 | -$14.44K 10-Q · filed 2019-08-09 | -$12.69K 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $1.75K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |